Skip to main content
Clinical Trials/CTRI/2025/10/095573
CTRI/2025/10/095573
Not yet recruiting
Phase 3

Randomized Control Trial Comparing Efficacy of Benzydamine Mouth wash Vs Oral Honey Gargle in Prevention & Control of Oral Mucositis in Post- Operative Cases of Head & Neck Cancer receiving Adjuvant Radiotherapy.

Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital1 site in 1 country212 target enrollmentStarted: October 31, 2025Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital
Enrollment
212
Locations
1
Primary Endpoint
To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system).

Overview

Brief Summary

Head and neck carcinomas are the most common cancer in India with oral cavity being the most common subsite and squamous cell carcinoma being the most common histology. Carcinoma of oral cavity is mostly confined to the primary site, with locoregional spread. Distant metastases are seen infrequently. Management of choice is usually definitive surgery, followed by adjuvant Radiotherapy with or without concurrent chemotherapy.

Radiotherapy is delivered by using varying techniques. IMRT plays a critical role in the management of patients with head and neck (H&N) cancer. The advantage of IMRT over older/conventional techniques is that it can conform the dose to any complex target volume and avoid critical Organs at Risk (OARs).

Oral mucositis is a frequent and distressing complication of adjuvant RT in patients treated for head and neck cancers. It significantly impairs oral intake, quality of life, and may necessitate treatment breaks, thereby compromising oncologic outcomes. Benzydamine mouthwash is currently recommended for mucositis prevention but may be associated with limitations such as availability, cost, and poor patient acceptability. Honey, a natural substance with proven anti-inflammatory and wound-healing properties, has shown potential in reducing mucositis severity in preliminary studies.

However, there is a lack of robust, randomized controlled trials comparing honey gargle directly with Benzydamine mouthwash in this clinical setting. This study seeks to address this gap by evaluating whether honey gargle is non-inferior to Benzydamine mouthwash in preventing and controlling oral mucositis among post-operative head and neck cancer patients receiving adjuvant RT.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Histologically proven squamous cell carcinoma of oral cavity. 2.Age.
  • 18 to 70 years 3.Both sexes 4.ECOG (Eastern Cooperative Oncology Group) 0-2 5.Adequate surgical resection of primary and nodal disease 6.Non-metastatic disease (T1-T4a, N0-3b). 7.Patients planned for adjuvant RT only with RT dose ranging from 60-64Gy in conventional fractions. 8.Patient able to read and write in their vernacular language.

Exclusion Criteria

  • 1.Patients with more than or equal to grade 2 trismus.
  • 2.Pregnant or lactating women 3.Any histopathology other than Squamous cell carcinoma 4.Patient requiring concurrent chemotherapy.
  • 5.Synchronous or Metachronous malignancy.
  • 6.Metastatic disease (any T, any N, M1).

Outcomes

Primary Outcomes

To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system).

Time Frame: To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system). | Secondary objective- | 1. Duration of relief of oral mucositis. | 2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment. | 3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

Secondary objective-

Time Frame: To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system). | Secondary objective- | 1. Duration of relief of oral mucositis. | 2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment. | 3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

1. Duration of relief of oral mucositis.

Time Frame: To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system). | Secondary objective- | 1. Duration of relief of oral mucositis. | 2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment. | 3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment.

Time Frame: To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system). | Secondary objective- | 1. Duration of relief of oral mucositis. | 2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment. | 3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

Time Frame: To assess the efficacy [percentage of cases developing higher grade (3 and 4) of oral mucositis] of oral honey wash and gargle versus Benzydamine mouth wash in prevention and control of acute oral mucositis evaluated using radiation therapy oncology group (RTOG grading system). | Secondary objective- | 1. Duration of relief of oral mucositis. | 2. Frequency of high-grade (Grade 3 and 4) oral mucositis during treatment. | 3. Assessment of quality of life, local pain palliation via [Wong Baker Faces Pain Scale] in patients at start of RT, 6 weeks and 12 weeks post-RT.

Secondary Outcomes

  • Secondary objective-(1. Duration of relief of oral mucositis.)

Investigators

Sponsor
Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr Ashutosh Mukherji

Mahamana Pandit Madanmohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Varanasi

Study Sites (1)

Loading locations...

Similar Trials